Company intelligence / Profile preview

Galisar

Foster City, California, United States

Ownership: Private
Development stage: Other

Overview

Galisar was a biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting G protein-coupled receptors (GPCRs). The company's primary research program centered on GPR119 agonists, which were being investigated for the treatment of type 2 diabetes and related metabolic disorders. Galisar's approach leveraged expertise in GPCR pharmacology to identify compounds that could stimulate insulin secretion and improve glucose homeostasis. In 2011, the company was acquired by Gilead Sciences to bolster Gilead's metabolic disease pipeline and GPCR research capabilities.

Therapeutic areas: Endocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Galisar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galisar.

Explore the full profile